Evidence map›Paper›PMID 34931201›Full record

ArticlemedRxiv : the preprint server for health sciences2021

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.

Wilfredo F Garcia-Beltran, Kerri J St Denis, Angelique Hoelzemer, Evan C Lam, Adam D Nitido, Maegan L Sheehan, Cristhian Berrios, Onosereme Ofoman, Christina C Chang, Blake M Hauser and 7 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 123 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Wilfredo F Garcia-BeltranThese authors contributed equally.
Kerri J St DenisThese authors contributed equally.
Angelique HoelzemerFirst Department of Internal Medicine, Division of Infectious Diseases, University Medical Centre Eppendorf, Hamburg, Germany.
Evan C LamRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Adam D NitidoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Maegan L SheehanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Cristhian BerriosDepartment of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
Onosereme OfomanDepartment of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
Christina C ChangCenter for the AIDS Programme of Research in South Africa, Durban, 4001, South Africa.
Blake M HauserRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Jared FeldmanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
David J GregoryVaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, 02129, USA.
Mark C PoznanskyVaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, 02129, USA.
Aaron G SchmidtRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
A John IafrateDepartment of Pathology, Massachusetts General Hospital, Boston, MA, 02114, USA.
Vivek NaranbhaiCenter for the AIDS Programme of Research in South Africa, Durban, 4001, South Africa.
Alejandro B BalazsRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA.
Ragon Institute of MGH, MIT and Harvard · USMassachusetts General Hospital · USCentre for the AIDS Programme of Research in South Africa · ZAUniversität Hamburg · DE

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
MOLECULAR BASIS OF VIRAL INFECTIVITYT32AI007245 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Aaron Gregory Schmidt · 1985 to 2026
$11.3M
Epitope focusing to the receptor binding motif for a universal coronavirus vaccineR01AI146779 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SCHMIDT, AARON GREGORY · 2019 to 2023
$4.2M
Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
NIAID NIH HHS R01 AI146779NIAID NIH HHS T32 AI007245NIDA NIH HHS DP2 DA040254NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529) harboring up to 36 mutations in spike protein, the target of vaccine-induced neutralizing antibodies. Given its potential to escape vaccine-induced humoral immunity, we measured neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.COV2.S vaccine recipients against wild type, Delta, and Omicron SARS-CoV-2 pseudoviruses. We included individuals that were vaccinated recently (<3 months), distantly (6-12 months), or recently boosted, and accounted for prior SARS-CoV-2 infection. Remarkably, neutralization of Omicron was undetectable in most vaccinated individuals. However, individuals boosted with mRNA vaccines exhibited potent neutralization of Omicron only 4-6-fold lower than wild type, suggesting that boosters enhance the cross-reactivity of neutralizing antibody responses. In addition, we find Omicron pseudovirus is more infectious than any other variant tested. Overall, this study highlights the importance of boosters to broaden neutralizing antibody responses against highly divergent SARS-CoV-2 variants.

Identifiers

PMID34931201
PMCPMC8687472
OpenAlexW4200104787

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.